0001209191-14-074579.txt : 20141211 0001209191-14-074579.hdr.sgml : 20141211 20141211171000 ACCESSION NUMBER: 0001209191-14-074579 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141209 FILED AS OF DATE: 20141211 DATE AS OF CHANGE: 20141211 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doberstein Stephen K CENTRAL INDEX KEY: 0001480111 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 141281528 MAIL ADDRESS: STREET 1: 129 ELSIE STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94110 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-12-09 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001480111 Doberstein Stephen K C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 0 1 0 0 SVP & Chief Scientific Officer Stock Option 16.31 2014-12-09 4 A 0 50000 0.00 A 2022-12-08 Common Stock 50000 50000 D Stock Option 16.31 2014-12-09 5 A 0 E 50000 0.00 A 2022-12-08 Common Stock 50000 50000 D This option was granted on December 9, 2014 and vests in monthly installments over the four-year period following the grant date. This stock option is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the shares subject to the option become vested and exerciseable. The time-based vesting is on a monthly pro-rata basis over a period of 4 years from the grant date (December 9, 2014). The performance-based vesting condition will be met only if Nektar (or a licensee) files, within five years following the grant date, a new drug registration with the FDA or the European Medicines Agency for a significant drug candidate program (average royalty >7.5%) including, without limitation, the following: (1) etirinotecan pegol; (2) NKTR-061/Amikacin Inhale; (3) Ciprofloxacin Dry Powder for Inhalation; or (4) NKTR-181 (an oral opioid analgesic drug candidate). Gilbert M. Labrucherie, Jr., Attorney-in-Fact 2014-12-11